Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard*, Jair Bar, Pilar Garrido, Marina C. Garassino, Fiona McDonald, Françoise Mornex, Andrea R. Filippi, Hans J.M. Smit, Solange Peters, John K. Field, Daniel C. Christoph, Anne Sibille, Rainer Fietkau, Vilde D. Haakensen, Christos Chouaid, Ben Markman, T. Jeroen N. Hiltermann, Alvaro Taus, William Sawyer, Allison AllenPratibha Chander, Muriel Licour, Benjamin Solomon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy (CRT). The observational PACIFIC-R study assesses the real-world effectiveness of durvalumab in patients from an early access program. Here, we report treatment characteristics and a preplanned analysis of real-world progression-free survival (rwPFS). Methods: PACIFIC-R (NCT03798535) is an ongoing, international, retrospective study of patients who started durvalumab (intravenously; 10 mg/kg every 2 wk) within an early access program between September 2017 and December 2018. The primary end points are investigator-assessed rwPFS and overall survival (analyzed by Kaplan–Meier method). Results: As of November 30, 2020, the full analysis set comprised 1399 patients from 11 countries (median follow-up duration, 23.5 mo). Patients received durvalumab for a median of 11.0 months. Median rwPFS was 21.7 months (95% confidence interval: 19.1–24.5). RwPFS was numerically longer among patients who received concurrent versus sequential CRT (median, 23.7 versus 19.3 mo) and among patients with programmed cell death-ligand 1 expression greater than or equal to 1% versus less than 1% (22.4 versus 15.6 mo). Overall, 16.5% of the patients had adverse events leading to treatment discontinuation; 9.5% of all patients discontinued because of pneumonitis or interstitial lung disease. Conclusions: Consolidation durvalumab after definitive CRT was well tolerated and effective in this large, real-world cohort study of patients with unresectable, stage III NSCLC. As expected, rwPFS was longer among patients who received concurrent versus sequential CRT and patients with higher programmed cell death-ligand 1 expression. Nevertheless, favorable rwPFS outcomes were observed regardless of these factors.

Original languageEnglish
Pages (from-to)181-193
Number of pages13
JournalJournal of Thoracic Oncology
Volume18
Issue number2
DOIs
StatePublished - Feb 2023

Funding

FundersFunder number
AstraZenecaNCT03798535

    Keywords

    • Consolidation therapy
    • Immunotherapy
    • Locally advanced NSCLC
    • PD-L1 inhibition
    • Real-world data

    Fingerprint

    Dive into the research topics of 'Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study'. Together they form a unique fingerprint.

    Cite this